Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: pale (37), ashen (1), drawn (152)

Annual-report-24-25-final

Description: 2024/25 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2024/25 Presented to Parliament
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/Annual-report-24-25-final.pdf

Tisacel-Cytarabine (500)-Etoposide (150)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – TISACEL – CYTARABINE (500) – ETOPOSIDE (150) Regimen This regimen
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Tisacel-Cytarabine-500-Etoposide-150.pdf

Tisacel - Cyclophosphamide (500) - Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – TISACEL– CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) Regimen This r
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Tisacel-Cyclophosphamide-500-Fludarabine-30-Ver1.pdf

Transient ischemic attack (TIA) - patient information

Description: Transient ischemic attack (TIA) Information for patients You have been given this booklet because you have been referre
Url: /Media/UHS-website-2019/Patientinformation/Brain-and-spine/Transient-ischemic-attack-TIA-685-PIL.pdf

Cytarabine(SC)-Venetoclax

Description: Chemotherapy Protocol Acute Myeloid Leukaemia CYTARABINE (SC) - VENETOCLAX Regimen  AML – Cytarabine (SC) -Venetoclax Indication  Newly diagnosed
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/CytarabineSC-Venetoclax.pdf

Enhanced recovery after oesophagogastric surgery (EROS) - patient information

Description: This leaflet explains what the enhanced recovery programme involves following oesophagogastric surgery (EROS).
Url: /Media/UHS-website-2019/Patientinformation/Surgery/Enhanced-recovery-after-oesophagogastric-surgery-EROS-1404-PIL.pdf

UHS Our People Strategy 2022 - 2026

Description: OUR PEOPLE STRATEGY 2022 to 2026 CONTENTS 05 Foreword by Steve Harris – chief people officer 06 Our strategic framework 07
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Plans-and-strategies/UHS-Our-People-Strategy-2022-2026.pdf

Welcome to Burley ward - patient information

Description: A guide to your stay on Burley ward.
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Welcome-to-Burley-ward-2836-PIL.pdf

BEACOPP escalated

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONEPROCARBAZINE-VINCRISTINE (BEACOPP
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPP-escalated.pdf

BEACOPP 14

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONEPROCARBAZINE-VINCRISTINE (BEACOPP
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPP-14.pdf

161 to 170 of 199

Previous … 15 16 17 18 19 … Next